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The Thyroid Hormone Receptors 
Inhibit Hepatic Interleukin-6 
Signaling During Endotoxemia
Constanza Contreras-Jurado1,*, Elvira Alonso-Merino1,*, Cristina Saiz-Ladera1, 
Arturo José Valiño1, Javier Regadera2, Susana Alemany1 & Ana Aranda1
Decreased thyroidal hormone production is found during lipopolysaccharide (LPS)-induced endotoxic 
shock in animals as well as in critically ill patients. Here we studied the role of the thyroid hormone 
receptors (TRs) in activation of STAT3, NF-κB and ERK, which play a key role in the response to 
inflammatory cytokines during sepsis. TR knockout mice showed down-regulation of hepatic 
inflammatory mediators, including interleukin 6 (IL-6) in response to LPS. Paradoxically, STAT3 and 
ERK activity were higher, suggesting that TRs could act as endogenous repressors of these pathways. 
Furthermore, hyperthyroidism increased cytokine production and mortality in response to LPS, despite 
decreasing hepatic STAT3 and ERK activity. This suggested that TRs could directly repress the response 
of the cells to inflammatory mediators. Indeed, we found that the thyroid hormone T3 suppresses IL-6 
signalling in macrophages and hepatocarcinoma cells, inhibiting STAT3 activation. Consequently, the 
hormone strongly antagonizes IL-6-stimulated gene transcription, reducing STAT3 recruitment and 
histone acetylation at IL-6 target promoters. In conclusion, TRs are potent regulators of inflammatory 
responses and immune homeostasis during sepsis. Reduced responses to IL-6 should serve as a 
negative feedback mechanism for preventing deleterious effects of excessive hormone signaling during 
infections.
Sepsis is characterized by an excessive inflammatory response to infection and is a major cause of mortality1. 
Endotoxic shock, the most lethal form of sepsis, is caused by lipopolysaccharide (LPS), the main membrane com-
ponent of Gram-negative bacteria. The liver plays a critical role in innate and adaptive immunity. In response to 
infection and inflammation, the liver synthetizes acute-phase proteins (APPs), which are key components of the 
immune response to infection2,3. Innate immune responses triggered by LPS are mediated by Toll-like 4 receptors 
and involve the coordinated production of a large variety of inflammatory mediators, particularly Interleukin 6 
(IL-6) and Tumor Necrosis α (TNFα )4. Activation of Signal Transducer and Activator of Transcription 3 (STAT3) 
and Nuclear Factor kappa-Light-chain-enhancer of Activated B Cells (NF-κ B) by these cytokines plays a key 
role in the liver response to inflammation3, controlling the expression of a large number of genes5. IL-6 leads to 
activation of STAT3 and/or Ras–mitogen-activated protein kinase (MAPK) signaling6, while TNFα induces the 
activation of NF-κ B7. In response to IL-6, STAT3 is phosphorylated at tyrosine 7058, triggering dimerization and 
STAT translocation into the nucleus, where it binds to its consensus motifs in target genes, including APP genes2,9. 
Activation of STAT3 also induces a negative feedback involving induction of phosphatases and Suppressor of 
Cytokine Signaling 3 (SOCS3)10. In non-stimulated cells, cytoplasmic NF-κ B dimers are associated to inhibitory 
Iκ B proteins. In response to pro-inflammatory stimuli, such as TNFα , Iκ B is degraded, causing nuclear trans-
location and binding of NF-κ B to its cognate sequences11. Some of the target genes are common for NF-κ B and 
STAT3 and both transcription factors are engaged in positive and negative cross-talk2.
The actions of the thyroid hormones (L-thyroxine, T4, and 3,3′ ,5-triiodo-L-thyronine, T3) are mediated by 
binding to nuclear receptors (TRα and TRβ ). These receptors act as ligand-dependent transcription factors by 
binding, generally as heterodimers with the retinoid X receptor (RXR), to thyroid hormone response elements 
in target genes or by modulating the activity of other transcription factors or signalling pathways12. There is 
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increasing evidence that the thyroid hormones could modulate immune responses13,14, but the molecular mech-
anisms involved in the cross-talk between thyroid hormone and immune function have not yet been clarified. 
On the other hand, illness results in a strong reduction in thyroid hormone production and in changes in thy-
roid hormone metabolism, a condition called the ‘sick euthyroid syndrome’ or ‘nonthyroidal illness syndrome’ 
(NTIS)15. LPS administration serves as a model for NTIS in mice16. During sepsis, thyroidal T4 and T3 synthe-
sis is down-regulated by cytokines17, expression of deiodinases responsible for thyroid hormone metabolism is 
altered16,18,19 and TRβ and RXR expression is reduced20,21.
We have previously shown that TRs can antagonize NF-κ B activation in a ligand-dependent manner in pitui-
tary cells22,23 and that they could modulate STAT3, NF-κ B and ERK activation in the skin in vivo24. This suggests 
that TRs could regulate inflammatory responses. In this work we demonstrate that these receptors control hepatic 
cytokine production and signalling during sepsis in vivo and that the thyroid hormone directly antagonizes IL-6 
signalling in cultured hepatocarcinoma cells and macrophages, leading to reduced STAT3 transcriptional activity.
Results
STAT3 and ERK over-activation in TR KO mice liver. To analyse whether TRs could modulate the 
activity of signalling pathways involved in immune responses, we used mice lacking TRα 1 and TRβ , the main 
thyroid hormone binding isoforms12. These animals are extremely resistant to the actions of the thyroid hor-
mones, presenting very high circulating levels of these hormones due to the lack of the feedback mechanism by 
which high thyroid hormone levels suppress pituitary thyroid-stimulating hormone25,26. Since liver inflammation 
and carcinogenesis show a clear gender disparity27, we measured the levels of total and phosphorylated STAT3 in 
male and female mice, finding that pSTAT3 levels were higher in the livers of KO animals of both sexes (Fig. 1A). 
Strongly increased ERK phosphorylation, without changes in total levels of the MAPK, and a weaker increase in 
p65/NF-κ B phosphorylation with minor changes in total p65 and Iκ Bs were also observed in TR KO mice.
The role of TRs in the liver response of these pathways to endotoxic shock was examined in male WT and 
TR KO mice sacrificed at 45 min or 4 h after injection of 5 mg/kg LPS (Fig. 1B). LPS treatment increased pSTAT3 
and pERK levels and this induction was stronger in mice lacking TRs. LPS also enhanced p65 phosphorylation 
and caused a transient Iκ Bα reduction, indicating NF-κ B activation in both groups, although pp65 levels were 
slightly higher and Iκ Bα levels were still low at 4 h in KO animals. This suggests that these signalling pathways 
could be could be more sensitive to LPS in TR KO mice. Therefore, we next examined the liver response to a lower 
LPS dose (1 mg/kg). This LPS concentration only induced significant phosphorylation of STAT3 and ERK in 
TR deficient mice, confirming that endogenous liver TRs exert a repressive effect in the activity of the examined 
pathways (Fig. 1C).
Since these differences could be due to altered cytokine production and IL-6 and TNFα appear to be key 
components of the hepatic response to LPS, we measured transcript levels of these cytokines in the livers of 
WT and KO mice. No significant differences were found between untreated WT and KO animals and the same 
occurred with the anti-inflammatory IL-10 cytokine or with SOCS3 mRNAs. In addition, treatment with 5 mg/kg 
LPS (Fig. 2A) or with 1 mg/kg LPS (Fig. 2B) resulted in the expected increase of TNFα and IL-6 transcripts, 
although IL-6 transcripts were lower in KO mice after 4 h of treatment with the higher LPS concentration. This 
was unexpected, since STAT3 phosphorylation is increased in these animals and IL-6 appears to be a major 
contributor for STAT activation under these conditions. We next determined the hepatic levels of chemokines 
and proinflammatory cytokines after 4 h treatment with 5 mg/kg LPS using cytokine arrays. TNFα , IL-6 and 
Figure 1. TRs deletion increases hepatic STAT3 and ERK activation. (A) Western blots with liver extracts of 
WT and TR KO mice and the indicated antibodies. Both male (M) and female (F) mice were used. (B) Protein 
levels assayed in male mice treated with vehicle or 5 mg/kg BW of LPS for the indicated time periods.  
(C) Similar experiment in WT and KO mice treated with 1 mg/kg BW LPS. Each band represents pooled 
samples from 3 different animals. Full-length blots are presented in Supplementary Figure 9.
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IL-10 are barely detectable in the arrays, but other inflammatory mediators show clear changes between WT 
and KO mice (Fig. 2C and Supplementary Fig. S1A). Thus, the levels of Cluster of Differentiation 54 (CD54), 
several interleukins or CXCL9 and CXCL10 were reduced in the livers of untreated TR KO mice. Cytokine and 
chemokine expression was strongly stimulated by LPS, and under these conditions differences between both 
groups were less marked, although decreased expression of some proteins was still observed in KO mice. These 
results show that despite presenting increased STAT3 and ERK phosphorylation, TR deficient mice have reduced 
hepatic levels of chemokines and pro-inflammatory cytokines. Since macrophages and other immune cells are the 
major cytokine-producing cells, we also measured the levels of circulating inflammatory cytokines (Fig. 2D and 
Supplementary Fig. S1B). In concordance with liver data, serum levels of several cytokines and chemokines were 
reduced in the untreated KO mice. Again LPS induced a strong increase in the expression of many inflammatory 
Figure 2. Cytokine expression in TR KO mice. (A) mRNA levels of TNFα , IL-6, IL-10 and SOCS3 in livers 
from WT and KO mice treated for 0 h, 45 min and 4 h with 5 mg/kg LPS. Data (means ± s.e) are expressed as 
fold-induction over the values obtained at time 0 in the untreated WT animals. Significance of Bonferroni 
post-hoc test (n = 3) between WT and KO mice is indicated. (B) Levels of the same mRNAs after injection of 
1 mg/kg LPS for the indicated times. (C) Levels of cytokines and chemokines in livers from WT and KO mice 
determined using a Mouse Cytokine Array. Extracts from livers of animals treated with vehicle (left panel) or 
with 5 mg/kg LPS for 4 h (right panel) were pooled and used in the assay. (D) Circulating levels of cytokines and 
chemokines in the same groups.
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mediators, and under these conditions no important differences between both groups were found. Of interest, 
serum levels of TNFα and IL-6 were strongly increased by LPS reaching similar levels in WT and KO animals.
Thyroid hormone administration reduces STAT3 and ERK activation in response to LPS. We 
next tested the possibility that excessive thyroid hormone signalling could be associated with the opposite phe-
notype to that found in TR KO mice. For this purpose, the response to LPS was analysed in euthyroid mice and 
in thyroid hormone treated mice. mRNA levels of Diodinase 1 (Dio 1), an accurate marker of hepatic thyroid 
hormone action were significantly higher in the thyroid hormone treated mice demonstrating tissue hyperthy-
roidism (Supplementary Fig. S2A,B). Mice were treated with vehicle or LPS at two different doses, 5 mg/kg or 
20 mg/kg BW. Of note, hyperthyroidism severely decreased survival during sepsis. Four out of six of the thyroid 
hormone-treated mice died within 2 h of injection with 20 mg/kg LPS, while all control animals appeared healthy 
and survived the treatment for at least 5 h. With the lower LPS dose, all euthyroid animals survived for 72 h, but 
hyperthyroid mice showed 100% mortality at this time (Fig. 3A). Therefore, only short-term experiments were 
performed to analyse the effect of hyperthyroidism in pathway activation and cytokine production in response to 
LPS. Opposite to the results obtained in TR-deficient mice, hyperthyroid livers showed reduced STAT3 and ERK 
phosphorylation in response to administration to either 5 mg/kg LPS (Fig. 3B) or 20 mg/kg LPS (Fig. 3C). NF-κ B 
activation was again demonstrated by rapid disappearance of Iκ Bα , which almost returned to normal levels after 
5 h. Also in contrast with the TR-deficient mice, p65 phosphorylation was lower in the untreated hyperthyroid 
mice and they showed a strongly reduced response to LPS treatment. Therefore, these signalling pathways appear 
to be altered in an opposite way by TR-deficiency and by thyroid hormone excess.
Also opposite to the results obtained in TRs KO mice, hyperthyroidism resulted in increased hepatic levels 
of IL-6 and SOCS3 transcripts in response to 5 mg/kg LPS (Fig. 4A) or 20 mg/kg LPS (Fig. 4B), while TNFα and 
IL-10 mRNAs remained unchanged. Cytokine profiling showed that thyroid hormone treatment increased basal 
expression of CD54, IL-16, CXCL9 or CXCL10 that were reduced in the KO mice (Fig. 4C and Supplementary Fig. 
3A). Again, LPS treatment (5 mg/kg for 5 h) strongly induced the levels of different chemokines and cytokines. 
Under these conditions differences between both groups were attenuated, although increased levels of some of 
these immune mediators were still observed in hyperthyroid mice. Serum levels of several proteins including 
CXCL10, CXCL11, CCL2 or G-CSF were also increased in hyperthyroid mice before LPS treatment (Fig. 4D and 
Supplementary Fig. S3B), although most of the differences between control and hyperthyroid animals again dis-
appeared after the treatment. Despite difference of IL-6 mRNA expression in the liver, circulating IL-6 levels were 
similarly induced by LPS in both groups.
Increased macrophage infiltration in hyperthyroid mice. To analyse if the observed changes in 
cytokine production and pathways activation were reflected in altered liver damage or infiltration of inflam-
matory cells, liver histology was performed in TR-deficient and hyperthyroid animals and their corresponding 
controls before and after treatment with LPS (5 mg/kg for 4–5 h). AST activity was not still enhanced at this early 
Figure 3. Reduced phosphorylation of STAT3, ERK and p65/NF-κB in hyperthyroid livers. (A) % survival 
of euthyroid and hyperthyroid male mice after treatment with 5 and 20 mg/kg LPS. (B) Western blots of the 
indicated proteins performed with liver extracts from control euthyroid (Euth.) and hyperthyroid (Hyperth.) 
mice. Mice were treated with vehicle or 5 mg/kg LPS for 5 h. Each band represents pooled extracts of 4–6 
animals. (C) Similar experiment in euthyroid and hyperthyroid mice treated with 20 mg/kg LPS for 45 min and 
5 h. Extracts from 4–6 animals were pooled except in the hyperthyroid group treated with LPS for 5 h, where 
only 2 mice survived. Full-length blots are presented in Supplementary Figure 9.
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time (Supplementary Figs S4A and S5A), but LPS treatment caused a detectable increase of the number of inflam-
matory cells inside the blood vessels in all groups. In all hyperthyroid animals, but not in other groups, sporadic 
necrotic foci with infiltrating macrophages were found after LPS-treatment (Supplementary Figs S4B and S5B,C). 
Furthermore, no liver damage that could explain early lethality in hyperthyroid mice treated with 20 mg/kg LPS 
was observed, discarding liver failure as responsible for death (Supplementary Fig. S6).
T3 reduces Il-6 signalling in cultured cells. The discrepancy between cytokine production and path-
way activation observed in vivo, suggested that the thyroid hormones could directly regulate cytokine sig-
nalling in hepatic cells. Therefore, we next tested STAT3 and ERK activation by IL-6 in cultured Hep3B cells 
(Fig. 5A). Phosphorylation of STAT3 and ERK was strongly and transiently induced by IL-6, but this induction 
was markedly blunted in T3-treated cells showing that the hormone inhibits IL-6 mediated activation of both 
signalling pathways. Similar results were obtained in cells cultured with 10% serum (Fig. 5A) and 0.5% serum 
(Supplementary Fig. S7). As expected, IL-6 did not cause Iκ B degradation or p65 phosphorylation illustrating 
that it does not activate NF-κ B (Supplementary Fig. S7). To analyse the effect of T3 on NF-κ B activation cells 
Figure 4. Cytokine levels in the liver and serum of hyperthyroid mice. (A) Levels of the indicated transcripts in 
livers from euthyroid and hyperthyroid mice treated for 0 and 5 h with 5 mg/kg LPS or vehicle. Data (means ± s.e of 
4–6 mice) are expressed as fold-induction over the values obtained at time 0 in the untreated controls. Significance 
of post-hoc ANOVA test between euthyroid and hyperthyroid animals is indicated with asterisks. (B) Levels of 
the same mRNAs after treatment with 20 mg/kg LPS for 0 h, 45 min and 5 h. (C) Quantification of cytokine and 
chemokine arrays in pooled livers from mice treated with vehicle (left panel) or with 5 mg/kg LPS for 5 h (right 
panel). (D) Circulating levels of cytokines and chemokines in the same animals.
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were treated with TNFα . TNFα did not stimulate STAT3 phosphorylation, but caused ERK activation, a rapid 
and transient disappearance of IKB and a detectable phosphorylation of p65 that were not significantly altered by 
T3 (Fig. 5B). The lack of inhibitory effect of T3 on the NF-κ B response to TNFα was confirmed under low serum 
conditions (Supplementary Fig. S7).
To test the effect of T3 in STAT3-dependent transcriptional activity, we performed transient transfection 
assays with a reporter plasmid bearing STAT-binding elements in Hep3B cells. IL-6 markedly stimulated the 
activity of the reporter, and T3 strongly antagonized this response (Fig. 5C). In contrast, the hormone did not 
reduce significantly activation by TNFα of a reporter plasmid containing NF-κ B binding sites (Fig. 5D). Since 
several genes encoding APPs contain STAT-responsive sites in their regulatory regions2,9, we next examined the 
effect of T3 in IL-6 mediated stimulation of APP transcript levels. As shown in Fig. 6A, IL-6 caused a significant 
increase on C-Reactive Protein (CRP), Haptoglobin and Hepcidin mRNA levels that was strongly antagonized 
in T3-treated cells. In Hep3B cells the expression of the Serum Amiloid A-1 (SAA1) or SOCS3 genes was not 
responsive to IL-6 and consequently T3 did not alter their levels. In addition, transcripts of the IL6 receptor or 
Glycoprotein 130 (Gp130), the common subunit of the type I cytokine receptor, essential for IL-6 signal trans-
duction were not altered by T3. Finally, and in agreement with previous results β –Fibrinogen gene expression was 
stimulated by T328 and also by IL-6.
To evaluate STAT3 recruitment to target promoters in vivo, ChIP assays were performed with chromatin from 
Hep3B cells treated with IL-6 and/or T3 (Fig. 6B). Un-stimulated cells did not show significant STAT3 binding to 
the CRP or Hepcidin promoter regions containing STAT3 response elements2,3. However, STAT3 was recruited to 
the promoters in IL-6-treated cells, and T3 significantly reduced this response in agreement with the repression 
of endogenous gene activation. The abundance of acetylated histone H4, a marker for transcriptional activation, 
followed a similar pattern since T3 also suppressed IL-6 dependent increase of histone acetylation (Fig. 6B).
As macrophages are major cytokine-producing cells, playing a key role in the response to endotoxemia, 
we also examined how the hormone affected LPS, IL-6 or TNFα signalling in these cells. T3 strongly reduced 
LPS-induced STAT3 phosphorylation in primary cultures of macrophages and in the murine RAW264.7 mac-
rophage cell line, while having minor effects in ERK or NF-κ B activation (Fig. 7A). This reduction was not due 
to a lower cytokine production in response to the endotoxin, since TNFα and IL-6 mRNA induction by LPS was 
similar in control and T3-treated cells (Fig. 7B). T3 also markedly reduced pSTAT3 levels in response to IL-6, but 
did not alter the NF-κ B response to TNFα in RAW264.7 macrophages (Supplementary Fig. S8). Therefore, T3 is 
also a strong antagonist of IL-6 signalling in macrophages.
Figure 5. T3 antagonizes IL-6 signaling in Hep3B cells. (A) Proteins were extracted from Hep3B cells 
pretreated with 5 nM T3 in 10% thyroid hormone-depleted serum for 36 h and then treated with 10 ng/ml IL-6 
for times ranging from 0 to 120 min. The levels of phosphorylated and total STAT3 and ERK were assessed by 
Western blot. (B) Western blot analysis of the indicated proteins in cells pretreated with T3 and then incubated 
with 10 ng/ml TNFα for varying times. Full-length blots are presented in Supplementary Fig. 9. (C) Cells were 
transiently transfected with a reporter plasmid containing STAT binding sites and incubated in the presence and 
absence of T3 for 36 h and with IL-6 for the last 5 h. (D) Luciferase activity in cells transfected with a reporter 
plasmid containing NF-kB binding sites and treated with T3 for 36 h and/or TNFα for the last 5 h.
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Discussion
Here we report a novel role for TRs and their ligands, the thyroid hormones, in the activation of signalling path-
ways that play an essential role in liver homeostasis and inflammation. STAT3 phosphorylation, which mediates 
dimerization, nuclear translocation and transcriptional stimulation8, was increased in the livers of genetically 
modified mice lacking TRs. Hepatic ERK phosphorylation was also enhanced and a modest increase of p65 
phosphorylation was also detected. Augmented activation of these signalling molecules was also found after 
LPS treatment, the archetypical inflammatory stimulus causing sepsis and endotoxic shock. In view of these 
results, our initial working hypothesis was that TRs could play a repressor role in the production of cytokines 
and chemokines that are crucial in the recruitment of inflammatory cells and that are in turn prominent amongst 
STAT3, ERK and NF-κ B targets are genes29. Surprisingly, induction of IL-6, the main cytokine responsible for 
hepatic STAT3 activation during sepsis, was reduced in TR deficient mice. An increase in circulating IL-6 that 
could reach the hepatic cells and account for the increased STAT3 activation was also dismissed. Although STAT3 
is predominantly activated by IL-6, other cytokines such as IL-10 also activate this transcription factor30,31. 
However, no changes in IL-10 were observed and therefore increased STAT activity in TR-deficient livers cannot 
Figure 6. T3 represses transcriptional activation of STAT3-dependent genes by IL-6. (A) Levels of the 
indicated transcripts (means ± s.d) determined in Hep3B cells treated with 5 nM T3 for 36 h and with IL-6 for 0, 
1 and 6 h. Significance of post-hoc ANOVA test between cells treated with and without T3 is indicated. (B) ChIP 
assays with the indicated regions of the CRP and Hepcidin genes and antibodies against STAT3 or acetylated 
H4 (Ac.H4). Data are expressed of % of the input after subtracting the values obtained with a control IgG. One 
representative experiment out of 2 with similar results is shown.
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be attributed to increased production of this cytokine. Furthermore, when hepatic expression of an array of 
cytokines and chemokines, as well as their circulating levels, was measured it was found that their levels were 
generally lower in TR-deficient mice. These results indicate that increased STAT3 and ERK phosphorylation 
detected in these animals in response to LPS is most definitely not due to increased cytokine production, and 
they emphasize the important role of these receptors as endogenous repressors of these signalling pathways since 
they are overactive even in the presence of abnormally low levels of cytokines. Intriguingly, we have previously 
shown that increased cytokine content is found in the skin of TR-deficient mice in response to treatment with 
12-O-Tetradecanoylphorbol-13-acetate24. Therefore, the effect of TRs on cytokine production and inflammatory 
responses is a complex phenomenon that appears to differ depending on the tissue and type of inflammatory 
insult.
Excessive thyroid hormone signalling led in general to opposite hepatic changes to those observed in the TR 
KO mice. Increased production of several cytokines and chemokines was found in the liver and serum of thyroid 
hormone-treated animals. However, circulating levels of most of these proteins reached similar levels in euthyroid 
and hyperthyroid mice after endotoxic shock, probably reflecting that extrahepatic cytokine production is not 
greatly influenced by thyroid hormone treatment. Under these conditions, hepatic expression of the IL-6 gene is 
more sustained in LPS treated hyperthyroid mice, despite presenting similar circulating levels of this cytokine. 
Again, there was a clear dissociation between the levels of inflammatory mediators and hepatic STAT3, ERK 
or NF-κ B activity, as phosphorylation of these signalling molecules was not increased but rather significantly 
reduced in hyperthyroid livers.
Figure 7. T3 reduces STAT3 activation in macrophages. (A) Western blot analysis of the indicated total and 
phosphorylated proteins in primary cultures of bone marrow macrophages (left) and RAW264.7 macrophages 
(right) pretreated with 5 nM T3 in 10% thyroid hormone-depleted serum for 36 h and then treated with 300 ng/
ml LPS for the indicated time points. Full-length blots are presented in Supplementary Figure 9. (A) Levels of 
TNFα and IL-6 mRNA (means ± s.d) in bone marrow and RAW264.7 macrophages treated with T3 for 36 h and 
with LPS for the last 6 h.
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Although the LPS dosages used were well tolerated by all control mice, thyroid hormone-treated mice 
showed increased lethality, indicating that they are more sensitive to the endotoxic shock caused by cytokine 
hyper-production. TNFα production is believed to account for the fatal shock syndrome, which includes a promi-
nent hepatic component32. Interestingly, lethality was associated with the specific up-regulated hepatic expression 
of IL-6, but not TNF-α in hyperthyroid mice. However, no changes in the hyperthyroid livers that could explain 
early lethality were found and therefore an extra-hepatic mechanism that remains to be defined should be respon-
sible for the reduced survival to endotoxic shock. Although STAT3 activation in hepatocytes could attenuate lethal-
ity in sepsis33, hypersensitivity to LPS induced endotoxic shock has been related to increased IL-6 production34. 
Therefore, reduced STAT3 activation might be involved in the increased mortality in hyperthyroid mice and a 
reduced response of the hepatic and/or extra-hepatic cells to this cytokine could represent a defence mechanism 
by which these animals could try to constrain sepsis-induced mortality. This is in line with the observation that 
thyroid hormone production by the thyroid gland is reduced not only after LPS administration in mice16 but also 
in NTIS in humans15. Interestingly, IL-6 appears to be involved in the development of this syndrome, since the 
drop in circulating thyroid hormones is reduced in IL-6 KO mice35.
The dissociated effects of the thyroid hormones in cytokine levels and the activation status of their signalling 
pathways suggested that these hormones could act directly in the liver cells or in other cells to repress cytokine 
signalling. We demonstrate that indeed liganded TRs directly interfere with inflammation-based cell signalling 
pathways in cultured Hep3B cells. T3 suppresses IL-6 signalling by inhibiting the activation of the main down-
stream targets of the cytokine: STAT3 and ERK. This was not due to reduced expression of the IL-6 receptors 
and therefore TRs appear to inhibit STAT3 activation downstream of binding of IL-6 to its cognate receptors. 
Furthermore, STAT3 phosphorylation in response to LPS was reduced by T3 in primary cultures of macrophages, 
as well as in the murine RAW264.7 macrophage cell line, although the hormone did not reduce the induction of 
IL-6 gene expression by the cytokine. STAT3 activation in response to incubation with IL-6 was also suppressed 
by T3 in macrophages, indicating that inhibition of IL-6 signalling by the thyroid hormones also occurs in these 
cells that have potent regulatory functions during infection and inflammation.
IL-6 is known to be a strong stimulator of APP gene expression in liver cells9. In addition to T3 being a 
counter-regulator of IL-6 stimulated STAT3 phosphorylation, the hormone also antagonized induction of APP 
genes in response to the cytokine, reducing STAT3 binding to their regulatory regions. Stimulation of transcrip-
tion by STAT factors involves the recruitment of coactivators with histone acetyltransferase activity36, and T3 also 
decreased the abundance of acetylated histone H4, a mark for transcriptional activation. Some of the examined 
genes such as SAA1 or even SOCS3 that contain STAT response elements and are well-known targets of this 
cytokine were not responsive to IL-6 in Hep3B cells, indicating the importance of the cell context and the limita-
tions of the cultured cell models. In any case, our results suggest that the thyroid hormone could counteract the 
response of liver cells to the cytokine excess produced in vivo under hyperthyroid conditions by reducing its tran-
scriptional actions and serving as a negative feedback defence mechanism. Besides this mechanism, inhibition 
of thyroidal secretion16, as well as the reduced expression of TR and its heterodimeric partner RXR20,21 should 
contribute to limit the deleterious effects of excess thyroid hormone signalling during LPS-induced sepsis.
The changes in p65 phosphorylation found in the livers of TR KO and hyperthyroid mice suggested that 
the liganded receptors could also antagonize NF-κ B activation that plays a crucial role in the response to 
pro-inflammatory cytokines. We have previously shown that T3 impairs NF-κ B activation by TNFα or by serum 
deprivation in pituitary tumour cells, causing a significant decrease of NF-kB-dependent transcription22,23. 
However, T3 did not reduce NF-kB activation by LPS in macrophages or by TNFα in Hep3B cells. In pituitary 
cells this inhibition involves the induction of the MAPK phosphatase, Dual Specificity Phosphatase 1. It is possi-
ble that this mechanism does not operate in macrophages or Hep3B cells. Therefore, more studies will be needed 
to clarify a possible antagonistic effect of TRs in NF-kB-activation in the liver in vivo.
The liver is a central organ in maintaining metabolic homeostasis and in controlling inflammatory responses 
during infection. The known functions of TRs in the liver have expanded from their well-known roles in regulating 
liver metabolism37, to also participate in liver regeneration26, senescence38, fibrosis39 and hepatocarcinogenesis40. 
In this study we show that these receptors are also potent regulators of immune homeostasis during sepsis, show-
ing a link between thyroid hormone signalling and STAT3 and ERK activation. Therefore, TRs may represent a 
confluence point of metabolic and inflammatory responses in the liver, suggesting that they could be important 
targets for developing new therapeutic strategies for the treatment of liver diseases. New thyromimetic drugs 
are being developed with the expectation that they could have beneficial effects in dyslipidemia, non-alcoholic 
fatty liver disease or even fibrosis. Our present results showing increased mortality to sepsis in thyroid hormone 
treated animals stress the importance of discovering novel ligands that could dissociate their beneficial metabolic 
effects from their potential danger in case of infections.
Methods
Animals and Treatments. All animal work was carried out in compliance with the European Community 
Law (86/609/EEC) and the Spanish law (R.D. 1201/2005), with approval of the Ethics Committee of the Consejo 
Superior de Investigaciones Científicas. Experiments were performed in livers from adult TRα 1−/−/TRβ −/− dou-
ble knockout (KO) mice and in wild-type TRα 1+/+/TRβ +/+ animals in a hybrid genetic background of 129/OLa+ 
129/Sv+ BALB/c+ C57BL/6. In addition, 8 weeks old wild-type male C57BL/6J mice bred at the Instituto de 
Investigaciones Biomédicas were made hyperthyroid by adding T4 (25 ng/g of mice) and T3 (95 ng/g of mice) in 
the drinking water during 15 days. Animals were injected i.p with the LPS (at concentrations varying from 1 to 
20 mg/kg BW) from Escherichia coli serotype 026:B6 Sigma–Aldrich, San Luis, MO) and sacrificed at different 
times. Serum was collected and livers samples were either frozen to obtain RNA and proteins or fixed with para-
formaldehyde and embedded in paraffin.
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Protein extraction and western-blotting. Livers were homogenized and total proteins were extracted 
in Ripa Buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 10% Glicerol, 1 mM EGTA, 1% Triton-X100, 1% Sodium 
Doxicolate, 0,1% SDS). Cells were harvested and lysed in triple-detergent lysis buffer (50 mM Tris-HCl pH 8.0, 
150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate). In all cases, phosphatase and protease inhibitor 
cocktail tablets (Roche, Basel, Switzerland) were added. Protein lysates were mixed with Laemmli sample buffer, 
boiled and loaded onto 8% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western analysis 
was performed using the antibodies and dilutions included in the Antibody Table.
Cytokine and Chemokine Quantification. R&D Systems Mouse Cytokine Array, Panel A (Catalog # 
ARY006, Minneapolis, MN), was used to simultaneously detect the levels of 40 different cytokines and chemok-
ines in 100 μ l serum or 400 μ g of whole-cell protein extracts obtained from livers from 3–4 animals per group and 
following the manufacturer specifications. Signals were detected by chemiluminiscence and were quantitated by 
scanning the X-ray films after different exposures (between 1 and 6 min) with ImageJ.
AST activity. Serum AST activity was measured in 32 μ l of a 1:3 dilution of sera with the Reflotron test 
(Roche), following the manufacturer’s instructions.
Real-time quantitative RT-PCR (qRT-PCR). RNA extraction, reverse transcription and quantitative PCR 
were performed as described previously38. The sequences of the oligonucleotides used in this study are listed in 
the Supporting Information.
Histology and Immunohistochemistry. Liver samples were fixed in 4% buffered formalin and embed-
ded in paraffin. Deparaffinized tissue sections were stained with H&E using standard procedures and images 
were obtained using a high-resolution Leica DC200 digital camera mounted on an Olympus DMLB microscope. 
Immunohistochemistry of the macrophage marker F4/80, a kind gift of Dr. Antonio Castrillo, was performed on 
4 μ m deparaffinized-rehydrated sections with 1:100 antibody dilution. Antigen retrieval was carried out with cit-
rate buffer and endogenous peroxidase activity was inhibited with 3% H2O2. Samples were blocked and incubated 
overnight with the antibody, and signal was amplified with the ABC Kit (Vectastin). Slides were revealed with 
DAB (Vector), counterstained with Hematoxylin and mounted with DePeX (Serva).
Cell culture. Hep-3B cells were grown in DMEM and RAW264.7 cells in RPMI with 10% FCS. Before the 
experiments cells were transferred to medium containing serum depleted of thyroid hormones by treatment with 
AG1-X8 resin. Bone marrow macrophages were obtained from the tibia and femur of 8 weeks-old C57-BL6 mice, 
plated and grown as previously described in DMEM and 30% medium conditioned by L929 fibroblasts41. After 6 
days the medium was changed to DMEM containing 10% resin-treated serum and treatments started.
Transient transfections and luciferase assays. Hep-3B cells were plated in DMEM with 10% FCS in 
24-well plates. After 24 h, cells were transfected in serum free medium with 300 ng of luciferase reporter plas-
mids containing consensus NF-kB and STAT3 binding sites23,42 and 50 ng of pRL-TK-Renilla (Promega, San 
Luis, CA) as a normalizer control, using Lipofectamine 2000 (InVitrogen, Carlsbad, CA). After 6 h cells were 
transferred to medium supplemented with 0.5% thyroid hormone-stripped serum by treatment with AG1-X8 
(Bio-Rad, Hercules, CA) resin. Cells were incubated with 5 nM T3 for 36 h in the presence and absence of IL-6 
(10 ng/ml) or TNFα (10 ng/ml) for the last 5 h. Luciferase activity was determined with the Dual Luciferase Assay 
System (Promega). Experiments were performed in triplicate and repeated three times. Data are mean ± s.d and 
are expressed as fold induction over the values obtained in the untreated cells.
ChIP assays. Hep-3B cells were plated in 150 mm dishes and after 24 h were washed and treated with 5 nM 
T3 for 36 h and/or 10 ng/ml IL6 for 2 h in medium containing 0.5% thyroid hormone-depleted serum. Cells 
were fixed and lysed following specifications of 17–295 Upstate kit, and sonicated in a Bioruptor UCD-200TM 
(Diagenode, Liège, Belgium). In each immunoprecipitation approximately 3 × 106 cells and 5 μ g of STAT3 anti-
body (sc-482(c-20)x), 1 μ g of acetylated histone H4 antibody (Upstate 06-866) or 3 μ g of normal rabbit IgG 
(sc-2027) were used. DNA was purified and precipitated. The promoter region of the C-Reactive Protein (CRP) 
promoter was amplified with the oligonucleotides 5′ -GAAATAATTTTGCTTCCCCTCTTCCC-3′ (forward) and 
5′ -TCCTAGATCTCTTGCCTTAGAGCTACCTCC-3′ (reverse), and the promoter of the Hepcidine gene with 
the oligonucleotides 5′ -CCCCACCCCCTGAACACA-3′ (forward) and 5′ -ACCGAGTGACAGTCGCTTTT-3′ 
(reverse). Results were normalized and are presented as a fraction of the inputs after subtracting the values 
obtained with the control IgG, which was always below 1% of the input chromatin.
Statistical analysis. Statistics were calculated with the SPSS software. Statistical significance of data 
was determined by applying ANOVA followed by the Bonferroni post- test. Results shown in the figures are 
means ± s.e. in experiments with animals or means ± s.d. in the experiments performed in cultured cells. P-values 
between WT and KO mice, euthyroid and hyperthyroid mice or cells treated with and without T3 are represented 
in the figures with asterisks: * P < 0.05, * * P < 0.01 and * * * P < 0.001.
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